Lung Clearance Index in cystic fibrosis subjects treated for Pulmonary Exacerbations

NIcole Sonneveld, Sanja Stanojevic, Reshma Amin, Paul Aurora, Jane Davies, Stuart Elborn, Alex Horsley, Philip Latzin, Katherine O'Neill, Paul Robinson, Emma Scrase, Hiran Selvadurai, Padmaja Subbarao, Liam Welsh, Sophie Yammine, Felix Ratjen

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)


Pulmonary exacerbations are important clinical events for cystic fibrosis (CF) patients. Studies assessing the ability of the lung clearance index (LCI) to detect treatment response for pulmonary exacerbations have yielded heterogeneous results. Here, we conduct a retrospective analysis of pooled LCI data to assess treatment with intravenous antibiotics for pulmonary exacerbations and to understand factors explaining the heterogeneous response.

A systematic literature search was performed to identify prospective observational studies. Factors predicting the relative change in LCI and spirometry were evaluated while adjusting for within-study clustering.

Six previously reported studies and one unpublished study, which included 176 pulmonary exacerbations in both paediatric and adult patients, were included. Overall, LCI significantly decreased by 0.40 units (95% CI -0.60 -0.19, p=0.004) or 2.5% following treatment. The relative change in LCI was significantly correlated with the relative change in forced expiratory volume in 1 s (FEV1), but results were discordant in 42.5% of subjects (80 out of 188). Higher (worse) baseline LCI was associated with a greater improvement in LCI (slope: -0.9%, 95% CI -1.0- -0.4%).

LCI response to therapy for pulmonary exacerbations is heterogeneous in CF patients; the overall effect size is small and results are often discordant with FEV1.
Original languageEnglish
Pages (from-to)1055-1064
Number of pages10
JournalEuropean Respiratory Journal
Issue number4
Publication statusPublished - Oct 2015


Dive into the research topics of 'Lung Clearance Index in cystic fibrosis subjects treated for Pulmonary Exacerbations'. Together they form a unique fingerprint.

Cite this